New Data Investigating Merck & Co.??’s KEYTRUDA (Pembrolizumab) In…
Merck , known as MSD outside the United States and Canada, today announced that new data evaluating KEYTRUDAA , the company’s anti-PD-1 therapy, in both advanced non-small cell lung cancer and malignant pleural mesothelioma will be presented as part of…